Clinical heterogeneity of seronegative myasthenia gravis

A. Evoli, A. P. Batocchi, M. Lo Monaco, S. Servidei, L. Padua, L. Majolini, P. Tonali

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We studied 38 patients affected by seronegative myasthenia gravis (SNMG) with age at the onset of the disease ranging from 6 to 66 yr. Clinical follow-up lasted at least 2 yr. Patients' lymphocyte cultures showed in no case anti-acetylcholine receptor antibody production; HLA associations did not differ significantly from those in seropositive MG. In most cases (33 out of 38) the disease differed from seropositive MG only in the low incidence of thymic pathology. In five cases the clinical picture was characterized by prevalent involvement of ocular and bulbar muscles and by a more stable course. These last group of patients did not respond satisfactorily to immunosuppressants, but they clearly improved with plasma-exchange. Mice injected with plasma IgG from four patients (two with typical clinical picture and two with prevalent oculobulbar involvement) showed a defect of neuromuscular transmission. In our experience, SNMG is a heterogeneous disease. A humorally mediated pathogenesis appears to be operating in both groups of patients we described.

Original languageEnglish
Pages (from-to)155-161
Number of pages7
JournalNeuromuscular Disorders
Volume6
Issue number3
DOIs
Publication statusPublished - May 1996

Fingerprint

Myasthenia Gravis
Plasma Exchange
Cholinergic Receptors
Immunosuppressive Agents
Age of Onset
Antibody Formation
Immunoglobulin G
Lymphocytes
Pathology
Muscles
Incidence

Keywords

  • Anti-AChR antibody
  • Myasthenia gravis
  • Seronegative myasthenia gravis
  • Thymectomy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Evoli, A., Batocchi, A. P., Lo Monaco, M., Servidei, S., Padua, L., Majolini, L., & Tonali, P. (1996). Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscular Disorders, 6(3), 155-161. https://doi.org/10.1016/0960-8966(96)00009-0

Clinical heterogeneity of seronegative myasthenia gravis. / Evoli, A.; Batocchi, A. P.; Lo Monaco, M.; Servidei, S.; Padua, L.; Majolini, L.; Tonali, P.

In: Neuromuscular Disorders, Vol. 6, No. 3, 05.1996, p. 155-161.

Research output: Contribution to journalArticle

Evoli, A, Batocchi, AP, Lo Monaco, M, Servidei, S, Padua, L, Majolini, L & Tonali, P 1996, 'Clinical heterogeneity of seronegative myasthenia gravis', Neuromuscular Disorders, vol. 6, no. 3, pp. 155-161. https://doi.org/10.1016/0960-8966(96)00009-0
Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscular Disorders. 1996 May;6(3):155-161. https://doi.org/10.1016/0960-8966(96)00009-0
Evoli, A. ; Batocchi, A. P. ; Lo Monaco, M. ; Servidei, S. ; Padua, L. ; Majolini, L. ; Tonali, P. / Clinical heterogeneity of seronegative myasthenia gravis. In: Neuromuscular Disorders. 1996 ; Vol. 6, No. 3. pp. 155-161.
@article{c06f1d36261e4e19a6b6a56641ad9a98,
title = "Clinical heterogeneity of seronegative myasthenia gravis",
abstract = "We studied 38 patients affected by seronegative myasthenia gravis (SNMG) with age at the onset of the disease ranging from 6 to 66 yr. Clinical follow-up lasted at least 2 yr. Patients' lymphocyte cultures showed in no case anti-acetylcholine receptor antibody production; HLA associations did not differ significantly from those in seropositive MG. In most cases (33 out of 38) the disease differed from seropositive MG only in the low incidence of thymic pathology. In five cases the clinical picture was characterized by prevalent involvement of ocular and bulbar muscles and by a more stable course. These last group of patients did not respond satisfactorily to immunosuppressants, but they clearly improved with plasma-exchange. Mice injected with plasma IgG from four patients (two with typical clinical picture and two with prevalent oculobulbar involvement) showed a defect of neuromuscular transmission. In our experience, SNMG is a heterogeneous disease. A humorally mediated pathogenesis appears to be operating in both groups of patients we described.",
keywords = "Anti-AChR antibody, Myasthenia gravis, Seronegative myasthenia gravis, Thymectomy",
author = "A. Evoli and Batocchi, {A. P.} and {Lo Monaco}, M. and S. Servidei and L. Padua and L. Majolini and P. Tonali",
year = "1996",
month = "5",
doi = "10.1016/0960-8966(96)00009-0",
language = "English",
volume = "6",
pages = "155--161",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Clinical heterogeneity of seronegative myasthenia gravis

AU - Evoli, A.

AU - Batocchi, A. P.

AU - Lo Monaco, M.

AU - Servidei, S.

AU - Padua, L.

AU - Majolini, L.

AU - Tonali, P.

PY - 1996/5

Y1 - 1996/5

N2 - We studied 38 patients affected by seronegative myasthenia gravis (SNMG) with age at the onset of the disease ranging from 6 to 66 yr. Clinical follow-up lasted at least 2 yr. Patients' lymphocyte cultures showed in no case anti-acetylcholine receptor antibody production; HLA associations did not differ significantly from those in seropositive MG. In most cases (33 out of 38) the disease differed from seropositive MG only in the low incidence of thymic pathology. In five cases the clinical picture was characterized by prevalent involvement of ocular and bulbar muscles and by a more stable course. These last group of patients did not respond satisfactorily to immunosuppressants, but they clearly improved with plasma-exchange. Mice injected with plasma IgG from four patients (two with typical clinical picture and two with prevalent oculobulbar involvement) showed a defect of neuromuscular transmission. In our experience, SNMG is a heterogeneous disease. A humorally mediated pathogenesis appears to be operating in both groups of patients we described.

AB - We studied 38 patients affected by seronegative myasthenia gravis (SNMG) with age at the onset of the disease ranging from 6 to 66 yr. Clinical follow-up lasted at least 2 yr. Patients' lymphocyte cultures showed in no case anti-acetylcholine receptor antibody production; HLA associations did not differ significantly from those in seropositive MG. In most cases (33 out of 38) the disease differed from seropositive MG only in the low incidence of thymic pathology. In five cases the clinical picture was characterized by prevalent involvement of ocular and bulbar muscles and by a more stable course. These last group of patients did not respond satisfactorily to immunosuppressants, but they clearly improved with plasma-exchange. Mice injected with plasma IgG from four patients (two with typical clinical picture and two with prevalent oculobulbar involvement) showed a defect of neuromuscular transmission. In our experience, SNMG is a heterogeneous disease. A humorally mediated pathogenesis appears to be operating in both groups of patients we described.

KW - Anti-AChR antibody

KW - Myasthenia gravis

KW - Seronegative myasthenia gravis

KW - Thymectomy

UR - http://www.scopus.com/inward/record.url?scp=0029892842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029892842&partnerID=8YFLogxK

U2 - 10.1016/0960-8966(96)00009-0

DO - 10.1016/0960-8966(96)00009-0

M3 - Article

VL - 6

SP - 155

EP - 161

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 3

ER -